Organogenesis repurchases 500K shares from director trust at $4.057/sh for $2M total

Organogenesis Holdings Inc.

Repurchase of 500,000 shares from GN 2016 Family Trust (related to director Glenn Nussdorf) at $4.057/share, total $2.03M.
Price based on 10-day trailing VWAP of common stock as of Nov 26, 2024.
Repurchase approved by Audit Committee and a Transaction Committee of the Board due to related-party nature.
Funded by proceeds from Nov 12, 2024 sale of Series A Convertible Preferred Stock to Avista Healthcare Partners.
Closing expected on or around December 3, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.